Aylin Ulku, MD, PhD

TitleAssistant Professor
InstitutionUniversity of California San Francisco
Address533 Parnassus Avenue
San Francisco CA 94117
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    Yale-New Haven Hospital2010Hugh Dwyer Award for Clincal Excellence

    Collapse Overview 
    Collapse Overview
    Aylin Ulku joined the faculty at UCSF in July 2012 as an Assistant Clinical Professor in the Division of Hospital Medicine. After completing her Combined Internal Medicine-Pediatrics Residency at Yale-New Haven Hospital, she continued as Chief Resident in the Primary Care Internal Medicine Residency at Waterbury/Yale-New Haven Hospitals. In 2010, she began work in Kigali, Rwanda, as an Assistant Clinical Professor for Yale School of Medicine, to assist in medical education capacity building within the National University of Rwanda (NUR) School of Medicine. Her work included direct teaching and clinical care supervising Rwandese medical students and residents in Internal Medicine and Pediatrics as well as collaboration with NUR and the Rwanda Ministry of Health in revising undergraduate and graduate curricula and training programs. Her clinical and research interests focus on global health education and training in non-communicable diseases in limited-resource settings.

    - Princeton University, Chemistry (BA)
    - University of North Carolina, Chapel Hill (MD-PhD - pharmacology)
    - Yale-New Haven Hospital (intership, residency, chief resident)

    Board Certifications:
    - Internal Medicine (2010)
    - Pediatrics (2010)

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Campbell PM, Singh A, Williams FJ, Frantz K, Ulkü AS, Kelley GG, Der CJ. Genetic and pharmacologic dissection of Ras effector utilization in oncogenesis. Methods Enzymol. 2006; 407:195-217. PMID: 16757325.
      View in: PubMed
    2. Pruitt K, Ulkü AS, Frantz K, Rojas RJ, Muniz-Medina VM, Rangnekar VM, Der CJ, Shields JM. Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem. 2005 Jun 17; 280(24):23363-70. PMID: 15831492.
      View in: PubMed
    3. Collette J, Ulku AS, Der CJ, Jones A, Erickson AH. Enhanced cathepsin L expression is mediated by different Ras effector pathways in fibroblasts and epithelial cells. Int J Cancer. 2004 Nov 01; 112(2):190-9. PMID: 15352030.
      View in: PubMed
    4. Eckert LB, Repasky GA, Ulkü AS, McFall A, Zhou H, Sartor CI, Der CJ. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res. 2004 Jul 01; 64(13):4585-92. PMID: 15231670.
      View in: PubMed
    5. Ulkü AS, Schäfer R, Der CJ. Essential role of Raf in Ras transformation and deregulation of matrix metalloproteinase expression in ovarian epithelial cells. Mol Cancer Res. 2003 Dec; 1(14):1077-88. PMID: 14707291.
      View in: PubMed
    6. Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem. 2003 Jul 25; 278(30):28045-51. PMID: 12732644.
      View in: PubMed
    7. Ulkü AS, Der CJ. Ras signaling, deregulation of gene expression and oncogenesis. Cancer Treat Res. 2003; 115:189-208. PMID: 12613198.
      View in: PubMed
    8. Fiordalisi JJ, Johnson RL, Ulkü AS, Der CJ, Cox AD. Mammalian expression vectors for Ras family proteins: generation and use of expression constructs to analyze Ras family function. Methods Enzymol. 2001; 332:3-36. PMID: 11305105.
      View in: PubMed